Close Menu

NEW YORK — Dutch diagnostics firm SkylineDx said on Monday that it has received a €20 million ($21.9 million) investment to further develop its melanoma test.

The funding is being provided by private investor Aat van Herk, and will be used to perform clinical testing of an assay — developed in collaboration with the Mayo Clinic — designed to predict the risk of a melanoma patient's cancer metastasizing in lymph nodes without the need for biopsy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.